MedTrace Logo

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

NCT00478686 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2017-05-08

No results posted yet for this study

Summary

The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.

Conditions

Interventions

PROCEDURE

Phlebotomy

5 to 7.5 milliliter (mL) Blood Sample

Sponsors & Collaborators

  • Myrexis Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Vicente Valero, MD · M.D. Anderson Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-23
Primary Completion
2017-05-02
Completion
2017-05-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478686 on ClinicalTrials.gov